Healthcare - Biotechnology - NASDAQ - US
$ 0.5315
-8.41 %
$ 31.4 M
Market Cap
-0.71
P/E
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.[ Read More ]
The intrinsic value of one ELEV stock under the base case scenario is HIDDEN Compared to the current market price of 0.531 USD, Elevation Oncology, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ELEV
FINANCIALS
0
REVENUE
-45.4 M
OPERATING INCOME
-45.7 M
NET INCOME
-56.2 M
OPERATING CASH FLOW
11.5 M
INVESTING CASH FLOW
48 M
FINANCING CASH FLOW
0
REVENUE
-13.2 M
OPERATING INCOME
-12.9 M
NET INCOME
-8.38 M
OPERATING CASH FLOW
-2.87 M
INVESTING CASH FLOW
10 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Elevation Oncology, Inc.
| Current Assets | 88 M |
| Cash & Short-Term Investments | 83.1 M |
| Receivables | 0 |
| Other Current Assets | 4.86 M |
| Non-Current Assets | 1.13 M |
| Long-Term Investments | 0 |
| PP&E | 59 K |
| Other Non-Current Assets | 1.07 M |
| Current Liabilities | 4.14 M |
| Accounts Payable | 507 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 3.64 M |
| Non-Current Liabilities | 30.1 M |
| Long-Term Debt | 30.1 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Elevation Oncology, Inc.
| Revenue | 0 |
| Cost Of Revenue | 39 K |
| Gross Profit | -39 K |
| Operating Expenses | 45.4 M |
| Operating Income | -45.4 M |
| Other Expenses | 259 K |
| Net Income | -45.7 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-83.39%
ROE
-51.30%
ROA
-53.53%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Elevation Oncology, Inc.
| Net Income | -45.7 M |
| Depreciation & Amortization | 39 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 3.34 M |
| Change in Working Capital | -13.7 M |
| Others | -8 M |
| Free Cash Flow | -56.2 M |
Wall Street Analysts Price Targets
Elevation Oncology, Inc.
Wall Street analysts predict an average 1-year price target for ELEV of $9 , with forecasts ranging from a low of $8 to a high of $10 .
ELEV Lowest Price Target
Wall Street Target
8 USD
1405.17%
ELEV Average Price Target
Wall Street Target
9 USD
1593.32%
ELEV Highest Price Target
Wall Street Target
10 USD
1781.47%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Elevation Oncology, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
May 25, 2022
|
Sell 2.9 M USD
|
venBio Global Strategic Fund III, L.P.
10 percent owner |
- 702737
|
4.1236 USD |
|
2 years ago
May 25, 2022
|
Sell 2.9 M USD
|
Royston Aaron
director: |
- 702737
|
4.1236 USD |
|
3 years ago
Jun 29, 2021
|
Bought 5 M USD
|
Qiming U.S. Healthcare Fund II, L.P.
10 percent owner |
+ 312500
|
16 USD |
|
3 years ago
Jun 29, 2021
|
Bought 3 M USD
|
Aisling Capital IV, LP
10 percent owner |
+ 187500
|
16 USD |
|
3 years ago
Jun 29, 2021
|
Bought 10 M USD
|
venBio Global Strategic Fund III, L.P.
10 percent owner |
+ 625000
|
16 USD |
|
3 years ago
Jun 29, 2021
|
Bought 4 M USD
|
Cormorant Asset Management, LP
|
+ 250000
|
16 USD |
|
3 years ago
Jun 29, 2021
|
Bought 4 M USD
|
Vertex Global HC Fund II Pte. Ltd.
10 percent owner |
+ 250000
|
16 USD |
7. News
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (ESMO-IO 2024) -- -- Expect to initiate dosing in combination portion of the Phase 1 trial of EO-3021 in 4Q 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 4Q 2024 -- BOSTON , Nov. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business achievements. "We continue to make significant progress with EO-3021, our potentially best-in-class Claudin 18.2 antibody-drug conjugate (ADC).
prnewswire.com
- 1 week ago
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 1 month ago
Empery Asset Management's Strategic Acquisition in Elevation Oncology
On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial). This transaction, executed at a price of $0.5999 per share, represents a notable increase in the firm's stake in the biotechnology company.
gurufocus.com
- 1 month ago
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy.
prnewswire.com
- 1 month ago
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J.
prnewswire.com
- 2 months ago
Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. A take on Easterly Government Properties suggests they offer reliable income similar to Treasury bonds with lower reinvestment risk. Bunge Global is seen as holding potential for market expansion opportunities despite its Q2 decline.
seekingalpha.com
- 3 months ago
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?
The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, or esophageal cancers.
benzinga.com
- 3 months ago
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON , Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent business achievements.
prnewswire.com
- 3 months ago
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer -- -- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/ hypoesthesia -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON , Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced promising initial data from the dose escalation portion of the ongoing Phase 1 clinical trial of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction (GEJ), pancreatic or esophageal cancers.
prnewswire.com
- 3 months ago
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings -- -- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 by mid-3Q 2024, with additional data in 1H 2025 -- BOSTON , June 27, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting.
prnewswire.com
- 4 months ago
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.
prnewswire.com
- 6 months ago
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being developed in the pipeline for the treatment of patients with HER3-expressning solid tumors; It has been shown that up to 42% of tumors express HER3. Nomination of ADC candidate for HER3-ADC clinical program expected in the 2nd half of 2024.
seekingalpha.com
- 6 months ago
8. Profile Summary
Elevation Oncology, Inc. ELEV
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 31.4 M
Dividend Yield
0.00%
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Contact
888 Seventh Avenue, New York, NY, 10106
https://elevationoncology.com
IPO Date
June 25, 2021
Employees
29
Officers
Mr. Joseph J. Ferra Jr.
Chief Executive Officer, President & Director
Ms. Tammy Furlong CPA, P.M.P.
Chief Financial Officer & Secretary
Mr. Biren Shah
Senior Vice President of Business & Corporate Development
Candice Masse
Senior Director of Corporate Communications & Investor Relations
Mr. Robert C. Yang
Senior Vice President & General Counsel
Mr. Ryan Bloomer
Head of Tech Ops
Dr. David Dornan Ph.D.
Chief Scientific Officer
Ms. Valerie Malyvanh Jansen M.D., Ph.D.
Chief Medical Officer